Prostate Cancer Foundation

donate ribbon

Donate Now    FAQs   Contact Us   Español   twitter   facebook

Navigation

Research News

PCF-Funded Discovery Results in a New Diagnostic Test to Diagnose Prostate Cancer

February 15, 2012 -- The US Food and Drug Administration (FDA) approved today a urine-based molecular diagnostic test that aids clinical decision-making for repeat prostate biopsies in men who have had a previous negative biopsy. This new test called the PROGENSA® PCA3 (Prostate Cancer Antigen 3) assay, tests for levels of PCA3 in the urine of men immediately after a Digital Rectal Examination. This test will potentially aid faster and more efficient diagnosis of prostate cancer. PCA3, the compound that this test checks for, is a gene that is normally expressed only in the human prostate tissue and is highly overexpressed in prostate cancer. The product of this gene, a noncoding RNA is excreted in the urine of patients with prostate abnormalities.
 
The current standard for prostate cancer screening employs the Prostate Specific Antigen (PSA) test which is prostate-specific but not highly cancer-specific. In contrast, PCA3 testing is highly cancer-specific, with better positive and negative predictive values compared to PSA testing.
With partial research support from the Prostate Cancer Foundation to Dr. William Isaacs at Johns Hopkins University in 1998, a gifted young woman scientist, Dr. Marion Bussemakers, from Radboud Universiteit Nijmegen in Holland, published a seminal research paper titled “DD3: a new prostate-specific gene, highly overexpressed in prostate cancer.” The work was a collaboration between a Baltimore Maryland-Nijmegen Holland research team, including leaders Jack Schalken and Dr. Fritz De Bruyne, as research progressed. This initial funding impetus by PCF has put PCA3 testing to FDA approval.

Read More at NASDAQ »

Back to Screening, Diagnosis, and Prognosis

Back to All Research News

Print | Bookmark and Share

2000 Programs Worldwide

Progress Reports

prostate cancer guides and books

prostate cancer clinical trials

patient support

athletes for a cure